Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Alpelisib | 1 | 72 | 0.01 | 6056.3 | 6091.5 | 1443.3 | -2.0 | 0.994 | 0.994 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.032 | 5912.0 | 6091.5 | 1443.3 | -1.49 | 0.971 | 0.971 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.1 | 5660.0 | 6091.5 | 1443.3 | -1.0 | 0.931 | 0.929 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 0.32 | 5140.8 | 6091.5 | 1443.3 | -0.495 | 0.843 | 0.844 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 1.0 | 3559.0 | 6091.5 | 1443.3 | 0.0 | 0.544 | 0.584 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 3.2 | 1584.5 | 6091.5 | 1443.3 | 0.505 | 0.046 | 0.260 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.001 | 5598.0 | 6240.0 | 1443.3 | -3.0 | 0.900 | 0.897 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.0032 | 5972.5 | 6240.0 | 1443.3 | -2.49 | 0.959 | 0.957 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.01 | 5904.0 | 6240.0 | 1443.3 | -2.0 | 0.948 | 0.946 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.032 | 6025.0 | 6240.0 | 1443.3 | -1.49 | 0.967 | 0.966 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.1 | 6019.8 | 6240.0 | 1443.3 | -1.0 | 0.966 | 0.965 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.32 | 6047.5 | 6240.0 | 1443.3 | -0.495 | 0.971 | 0.969 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 1.0 | 5741.0 | 6240.0 | 1443.3 | 0.0 | 0.923 | 0.920 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 3.2 | 5408.0 | 6240.0 | 1443.3 | 0.505 | 0.869 | 0.867 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.001 | 3773.0 | 5781.0 | 1443.3 | -3.0 | 0.616 | 0.653 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.0032 | 3719.8 | 5781.0 | 1443.3 | -2.49 | 0.605 | 0.643 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.01 | 3784.5 | 5781.0 | 1443.3 | -2.0 | 0.619 | 0.655 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.032 | 3677.3 | 5781.0 | 1443.3 | -1.49 | 0.595 | 0.636 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.1 | 3707.8 | 5781.0 | 1443.3 | -1.0 | 0.602 | 0.641 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.32 | 3776.0 | 5781.0 | 1443.3 | -0.495 | 0.617 | 0.653 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 1.0 | 3532.8 | 5781.0 | 1443.3 | 0.0 | 0.564 | 0.611 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Everolimus | 1 | 72 | 3.2 | 3453.3 | 5781.0 | 1443.3 | 0.505 | 0.546 | 0.597 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Pictilisib | 1 | 72 | 0.001 | 5849.5 | 6125.0 | 1443.3 | -3.0 | 0.956 | 0.955 | 2.085 | BT20 GDC0941 0 1 |
| BT-20 | Pictilisib | 1 | 72 | 0.0032 | 6083.5 | 6125.0 | 1443.3 | -2.49 | 0.993 | 0.993 | 2.085 | BT20 GDC0941 0 1 |
| BT-20 | Pictilisib | 1 | 72 | 0.01 | 6061.5 | 6125.0 | 1443.3 | -2.0 | 0.990 | 0.990 | 2.085 | BT20 GDC0941 0 1 |